Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir

被引：0

作者：

Younossi, Zobair M. ^{[1
,2
]}

Stepanova, Maria ^{[3
]}

Chan, Henry ^{[4
]}

Lee, Mei Hsuan ^{[5
]}

Yu, Ming-Lung ^{[6
,7
]}

Dan, Yock Young ^{[8
]}

Choi, Moon Seok ^{[8
]}

Henry, Linda ^{[3
,9
]}

机构：

[1] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA

[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[3] Ctr Outcomes Res Liver Dis, Washington, DC USA

[4] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China

[5] Natl Yang Ming Univ, Taipei 112, Taiwan

[6] Kaohsiung Med Univ, Hepatobiliary Div, Dept Internal Med, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[7] Kaohsiung Med Univ, Hepatitis Ctr, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[8] Natl Univ Singapore Hosp, Univ Med Cluster, Singapore 117548, Singapore

[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol, Seoul, South Korea

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2015年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1432

引用

页码：377 / 377

页数：1

共 50 条

[21] Ledipasvir-Sofosbuvir-Combination in chronic Hepatitis C?
Escher, Markus
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (25-26) : 13331 - 13331
[22] LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL
Younossi, Z.
Stepanova, M.
Marcellin, P.
Afdhal, N.
Nader, F.
Hunt, S.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S536 - S537
[23] THE IMPACT OF LEDIPASVIR (LDV)/SOFOSBUVIR (SOF) COMBINATION ON HEALTH-RELATED QUALITY OF LIFE (HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C (CH-C): THE SIRIUS STUDY
Younossi, Z.
Stepanova, M.
Pol, S.
Bronowicki, J. -P.
Carrieri, P.
Bourliere, M.
JOURNAL OF HEPATOLOGY, 2015, 62 : S591 - S591
[24] Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy
Aimono, Yuka
Kohyama, Noriko
Kamoshida, Toshiro
Yamamoto, Toshinori
Kogo, Mari
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (E1) : E29 - E34
[25] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
Abdelaty, Lamiaa N.
Elnaggar, Ahmed A.
Said, Amira A.
Hussein, Raghda R. S.
CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
[26] ADHERENCE TO EXPECTED TREATMENT DURATION FOR PATIENTS WITH HEPATITIS C TREATED WITH LEDIPASVIR/SOFOSBUVIR
Puenpatom, A.
Hull, M.
McPheeters, J.
Schwebke, K.
JOURNAL OF HEPATOLOGY, 2016, 64 : S744 - S745
[27] Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
Walsh, C. E.
Workowski, K.
Terrault, N. A.
Sax, P. E.
Cohen, A.
Bowlus, C. L.
Kim, A. Y.
Hyland, R. H.
Han, B.
Wang, J.
Stamm, L. M.
Brainard, D. M.
McHutchison, J. G.
von Drygalski, A.
Rhame, F.
Fried, M. W.
Kouides, P.
Balba, G.
Reddy, K. R.
HAEMOPHILIA, 2017, 23 (02) : 198 - 206
[28] Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir
Ou, Pengcheng
Chen, Jun
ANTIVIRAL THERAPY, 2018, 23 (03) : 283 - 284
[29] TNF-alpha is the Most Consistent Predictor of Impairment of Mental Health-Related Patient-Reported Outcomes (PROs) in Patients with Chronic Hepatitis C (CH-C) Treated with Ledipasvir (LDV) and Sofosbuvir (SOF) with or without Ribavirin (RBV)
Younossi, Zobair M.
Stepanova, Maria
Estep, James M.
Karrar, Azza
Oe, Bibiana
Elsheikh, Elzafir
Hariharan, Siddharth
Ahmed, Kazi
Tran, Patricia
Nader, Fatema
Henry, Linda
Weinstein, Ali A.
Gerber, Naomi Lynn
HEPATOLOGY, 2015, 62 : 372A - 372A
[30] Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C
Padidam, Sneha
Burke, Marie T.
Apple, Daniel B.
Hu, Jonathan K.
Lin, Xihui
JAMA OPHTHALMOLOGY, 2019, 137 (05) : 568 - 570

← 1 2 3 4 5 →